Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Genitourinary 1

Conditions

Prostatic Neoplasms 4Neoplasm Metastasis 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Leukemia, Myeloid, Chronic-Phase 2Glioblastoma 2Brain Neoplasms 2Adenocarcinoma of Lung 2Vaping 1Urinary Bladder Neoplasms 1Tobacco Use Disorder 1Stomach Neoplasms 1Solid Tumor 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligodendroglioma 1Neoplasms by Histologic Type 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × BID protein, human × Clear all
NCT02627677 2021-11-26

OPTIC-2L

Takeda

Phase 3 Terminated
44 enrolled 22 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡